Alzheimer's Disease Models
Creative Animodel offers an extensive portfolio of both in vitro and in vivo services in pharmacology and toxicology. Our rich-experienced scientists and state-of-art technique platforms assist the clients throughout every stage of the drug discovery process. We are now providing professional Alzheimer’s disease models to advance the understanding of pathology and discover effective therapeutics that prevent the neurodegenerative processes.
Alzheimer’s Disease: Symptoms and Pathology
Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that affects approximately 29.8 million people worldwide. It is the most common age-associated neurodegenerative disease, characterized by dementia and progressively worsening impairments to learning ability and memory skill, accompanied by a plethora of changes in personality, behavior, sleeping patterns, and functionality. Familial “early onset” (beginning in the third decade of life) of AD is rare, and almost all cases are considered “late onset” (>65 years); nevertheless, both diseases present with similar neurological and pathological traits.
The main pathologies that characterize AD include intracellular and extracellular aggregates of a small protein called amyloid beta (Aβ), generally referred to as senile plaques, and intracellular neurofbrillary tangles (NFTs) caused by aggregates of hyperphosphorylated tau protein. It is speculated that these toxic agents inhibit neural activity, induce neuronal cell death, and promote synaptic and dendritic loss. There also appears to be a strong link between noradrenergic degeneration, neuroinﬂammation, increased glial activation, and compromised serotonergic function with classic AD pathology. Lastly, the APOE ε4 genotype and TREM2 mutants have also been implicated as risk factors to AD.
Alzheimer’s Disease Models at Creative Animodel
Current therapies for AD mainly aim to inhibit the phosphorylation of tau protein, or reduce the level of Aβ peptides. However, few compounds show significant benefits in clinical trials. As part of our neuroscience portfolio, Creative Animodel offers a variety of AD models and related services that allow screening of novel drug candidates.
Model Characteristics and Pharmacology Evaluation
• Behavioral and cognitive tests: open field test and contextual fear conditioning test
• MRI and IHC imaging including relevant biomarkers
• Aβ measurement: soluble and insoluble
Creative Animodel offers end-to-end validated pre-clinical models and related services of pharmacology and toxicology. We support the global clients in model establishment, imaging modalities, behavioral tests as well as biomarker endpoint assays to help identify novel therapies for AD and other neurodegenerative diseases. Please feel free to contact us for more information.
1. Hau J, Schapiro SJ. Handbook of Laboratory Animal Science, Volume II, Third Edition: Essential Principles and Practices: CRC Press, 2010.